117 related articles for article (PubMed ID: 36700460)
1. Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Green JB; Merrill P; Lokhnygina Y; Mentz RJ; Alfredsson J; Holman RR;
Diabetes Obes Metab; 2023 Jun; 25(6):1473-1484. PubMed ID: 36700460
[TBL] [Abstract][Full Text] [Related]
2. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
[TBL] [Abstract][Full Text] [Related]
3. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Mentz RJ; Bethel MA; Gustavson S; Thompson VP; Pagidipati NJ; Buse JB; Chan JC; Iqbal N; Maggioni AP; Marso SP; Ohman P; Poulter N; Ramachandran A; Zinman B; Hernandez AF; Holman RR
Am Heart J; 2017 May; 187():1-9. PubMed ID: 28454792
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.
Badjatiya A; Merrill P; Buse JB; Goodman SG; Katona B; Iqbal N; Pagidipati NJ; Sattar N; Holman RR; Hernandez AF; Mentz RJ; Patel MR; Jones WS
Circ Cardiovasc Interv; 2019 Dec; 12(12):e008018. PubMed ID: 31752517
[TBL] [Abstract][Full Text] [Related]
5. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
Bethel MA; Mentz RJ; Merrill P; Buse JB; Chan JC; Goodman SG; Iqbal N; Jakuboniene N; Katona B; Lokhnygina Y; Lopes RD; Maggioni AP; Ohman P; Tankova T; Bakris GL; Hernandez AF; Holman RR
Diabetes Care; 2020 Feb; 43(2):446-452. PubMed ID: 31757838
[TBL] [Abstract][Full Text] [Related]
6. Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Reed SD; Li Y; Dakin HA; Becker F; Leal J; Gustavson SM; Kartman B; Wittbrodt E; Mentz RJ; Pagidipati NJ; Bethel MA; Gray AM; Holman RR; Hernandez AF;
Diabetes Care; 2020 Feb; 43(2):374-381. PubMed ID: 31806653
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.
Bethel MA; Stevens SR; Buse JB; Choi J; Gustavson SM; Iqbal N; Lokhnygina Y; Mentz RJ; Patel RA; Öhman P; Schernthaner G; Lecube A; Hernandez AF; Holman RR
Circulation; 2020 Apr; 141(17):1360-1370. PubMed ID: 32098501
[TBL] [Abstract][Full Text] [Related]
8. Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
Standl E; Stevens SR; Lokhnygina Y; Bethel MA; Buse JB; Gustavson SM; Maggioni AP; Mentz RJ; Hernandez AF; Holman RR;
Diabetes Care; 2020 Mar; 43(3):643-652. PubMed ID: 31882409
[TBL] [Abstract][Full Text] [Related]
9. Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus.
Barbery CE; Giczewska A; White J; Lokhnygina Y; Mentz RJ; Holman RR; Pagidipati N; Hernandez AF; Jones WS
Am Heart J; 2021 Sep; 239():59-63. PubMed ID: 33905751
[TBL] [Abstract][Full Text] [Related]
10. Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Davis TME; Giczewska A; Lokhnygina Y; Mentz RJ; Sattar N; Holman RR;
Cardiovasc Diabetol; 2022 Jun; 21(1):116. PubMed ID: 35761271
[TBL] [Abstract][Full Text] [Related]
11. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
[TBL] [Abstract][Full Text] [Related]
12. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Holman RR; Bethel MA; Mentz RJ; Thompson VP; Lokhnygina Y; Buse JB; Chan JC; Choi J; Gustavson SM; Iqbal N; Maggioni AP; Marso SP; Öhman P; Pagidipati NJ; Poulter N; Ramachandran A; Zinman B; Hernandez AF;
N Engl J Med; 2017 Sep; 377(13):1228-1239. PubMed ID: 28910237
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.
Holman RR; Bethel MA; George J; Sourij H; Doran Z; Keenan J; Khurmi NS; Mentz RJ; Oulhaj A; Buse JB; Chan JC; Iqbal N; Kundu S; Maggioni AP; Marso SP; Öhman P; Pencina MJ; Poulter N; Porter LE; Ramachandran A; Zinman B; Hernandez AF
Am Heart J; 2016 Apr; 174():103-10. PubMed ID: 26995376
[TBL] [Abstract][Full Text] [Related]
14. Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.
Mentz RJ; Bethel MA; Merrill P; Lokhnygina Y; Buse JB; Chan JC; Felício JS; Goodman SG; Choi J; Gustavson SM; Iqbal N; Lopes RD; Maggioni AP; Öhman P; Pagidipati NJ; Poulter NR; Ramachandran A; Reicher B; Holman RR; Hernandez AF;
J Am Heart Assoc; 2018 Oct; 7(19):e009304. PubMed ID: 30371301
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.
Ratner R; Han J; Nicewarner D; Yushmanova I; Hoogwerf BJ; Shen L
Cardiovasc Diabetol; 2011 Mar; 10():22. PubMed ID: 21410975
[TBL] [Abstract][Full Text] [Related]
16. Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
Alfredsson J; Green JB; Stevens SR; Reed SD; Armstrong PW; Angelyn Bethel M; Engel SS; McGuire DK; Van de Werf F; Hramiak I; White HD; Peterson ED; Holman RR;
Diabetes Obes Metab; 2018 Oct; 20(10):2379-2388. PubMed ID: 29923323
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
18. Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
van der Aart-van der Beek AB; van Raalte DH; Guja C; Hoogenberg K; Suchower LJ; Hardy E; Sjöström CD; Heerspink HJL
Diabetes Obes Metab; 2020 Sep; 22(9):1556-1566. PubMed ID: 32329160
[TBL] [Abstract][Full Text] [Related]
19. Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? Insights from post-hoc analysis of EXSCEL.
Gooding KM; Stevens S; Lokhnygina Y; Giczewska A; Shore AC; Holman RR
Diabetes Res Clin Pract; 2024 Jun; 212():111685. PubMed ID: 38670496
[TBL] [Abstract][Full Text] [Related]
20. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
